Aromatase Inhibitors and Growth Hormone for Short Stature in Boys
Author Information
Author(s): Wang Kan, Ye Fei, Wang Da-Yan, Lai Pan-Jian, Zhang Lin-Qian
Primary Institution: Jinhua Maternity and Child Health Care Hospital, Jinhua Women and Children’s Hospital, Jinhua, China
Hypothesis
Can the addition of aromatase inhibitors to growth hormone therapy improve growth outcomes in boys with short stature?
Conclusion
The study found that adding aromatase inhibitors to growth hormone therapy significantly improved growth velocity, predicted adult height, and bone age in boys with short stature.
Supporting Evidence
- The addition of aromatase inhibitors to growth hormone therapy resulted in a higher growth velocity.
- Participants receiving the combination therapy had a significantly higher predicted adult height.
- The combination therapy was associated with a younger bone age compared to growth hormone alone.
- No significant differences were found in adverse events between the two treatment groups.
Takeaway
This study shows that giving boys with short stature a medicine that blocks estrogen can help them grow taller when combined with growth hormone.
Methodology
The study conducted a meta-analysis of eight randomized controlled trials comparing the effects of aromatase inhibitors combined with growth hormone versus growth hormone alone.
Potential Biases
Potential publication bias was noted, particularly for growth velocity.
Limitations
The included studies had low to moderate quality, and the effects on adult height were not directly assessed.
Participant Demographics
Male children and adolescents with short stature, aged under 18.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI: 2.75–3.63 for growth velocity; 95% CI: 3.52–7.49 for predicted adult height; 95% CI: -1.06–-0.54 for bone age.
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website